Articles

Paula Aristizabal, MD, MAS, a pediatric hematologist/oncologist at Rady Children’s Hospital-San Diego/associate professor at the University of California San Diego, and her research team developed a peer navigation intervention known as the Childhood Malignancy Peer Research Navigation (Comprendo) program. This program pairs trained parent navigators—individuals who have experienced similar challenges with their own children’s cancer care—with parents who are newer to the experience, with the intention to guide these families through the informed consent process for childhood cancer clinical trials.

Value-Based Cancer Care is pleased to share with you that we are on site at the 21st Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, April 9-12, 2025, in Portland, OR and together with our sister publication, the Journal of Hematology Oncology Pharmacy,we are bringing you live coverage and abstracts from the meeting.

n the US cohort, Black patients with HR-positive/HER2-negative mBC who underwent NGS testing were more likely to receive first-line chemotherapy, less likely to have PIK3CA mutations, and less likely to receive first-line CDK4/6 inhibitors compared with White patients.

round Zero were 3 times more likely to have genetic changes associated with an increased risk of blood cancer compared with other first responders.

The researchers noted variations in time to treatment initiation and choice of therapy across the 3 healthcare settings, with factors such as distance from the hospital and income levels playing significant roles in delays of treatment.